Dr. Khorana on Blood Clots in Patients with Cancer

Video

In Partnership With:

Alok Khorana, MD, medical oncologist, Cleveland Clinic, discusses blood clot risk and treatment for patients with cancer.

Alok Khorana, MD, medical oncologist, Cleveland Clinic, discusses blood clot risk and treatment for patients with cancer.

On average, one-fifth of patients with cancer will experience a blood clot, says Khorana. For years, the standard of care for treating blood clots in cancer patients was low molecular weight heparins. More recently, direct oral anticoagulants have become common for the treatment of blood clots.

However, there have been no cancer patient-specific studies evaluating these new agents. Patients' absorption is different and they may have different interactions to these blood clots therapies than non-cancer therapies, says Khorana. In a collaboration with Janssen Pharmaceuticals, Cleveland Clinic is investigating these new agents in a cancer patient-specific trial.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD